In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Cabaletta Bio (CABA – Research Report), with a price target of $11.00. The company's shares closed last Friday at $1.49, close to its 52-week low of $1.17. According to TipRanks.com, Tsao is a 2-star analyst with an average return of 0.4% and a 38.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cabaletta Bio with a $15.33 average price target, implying a 995.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-cabaletta-bios-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Cabaletta Bio Charts.
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Cabaletta Bio Charts.